Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCORPIO-PEP ensitrelvir post-exposure prophylaxis study in household contacts of patients with COVID-19
jRCT2031230124Phase 3Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ensitrelvir with Placebo (2 arms). Started Jun 2023; status: active, not recruiting.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031230124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230124.